Entyvio® (vedolizumab)
A quick‑reference guide for clinicians, patients, and caregivers
| What it is | Vedolizumab is a humanized monoclonal antibody that selectively blocks the α4β7 integrin on lymphocytes, preventing them from homing to the gut. It’s marketed as Entyvio®. |
|----------------|----------------------------------------------------------------------------------------------|
| Approved indications | • Ulcerative colitis (UC) – moderate‑to‑severe disease that is inadequate or intolerant to standard therapy.
• Crohn’s disease (CD) – moderate‑to‑severe disease, including patients with inadequate response or intolerance to conventional therapy.
• Pediatric: 6–17 yr olds with UC; 6–17 yr olds with CD (under special circumstances). |
| Not approved for | • Psoriasis, eczema, rheumatoid arthritis, or any non‑intestinal autoimmune disease.
• Use as a first‑line agent; usually reserved for those who failed or cannot tolerate mesalamine, corticosteroids, immunomodulators, or TNF inhibitors. |
| Formulation & route | 300 mg (10 mL) in 100 mL saline. Intravenous infusion. |
| Dosing schedule | 1. Induction – 300 mg IV at Weeks 0, 2, and 6.
2. Maintenance – 300 mg IV every 8 weeks thereafter. (Some protocols use 150 mg every 4 weeks for high‑risk patients, but 300 mg/8 weeks is the standard). |
| Administration | 3–4 hour infusion in a clinical setting. Pre‑medication (e.g., acetaminophen, antihistamine) is not routinely required but may be given for patients with prior infusion reactions. |
| Mechanism of action | Blocks the interaction between α4β7 integrin and MAdCAM‑1 on gut endothelium, thereby reducing T‑cell migration into the GI tract. This spares systemic immunity, leading to a lower risk of systemic infections compared to anti‑TNF agents. |
| Key safety profile | • Infusion reactions – mild to moderate (fever, chills, rash).
• Infections – upper respiratory tract infections are most common; rare cases of opportunistic infections (e.g., histoplasmosis, tuberculosis).
• Malignancy – no consistent increase in lymphoma or other cancers, but long‑term data are still evolving.
• Reactivation of latent TB – similar risk to other biologics; screening required.
• Pregnancy – category B (animal studies show no risk, but human data limited). Avoid in pregnancy unless benefits outweigh potential risks.
• Breastfeeding – drug is excreted into milk; precaution advised. |
---
Before starting Vedolizumab
| Step | Details |
|------|---------|
| Baseline labs | CBC, CMP, CRP/ESR, Hepatitis B/C serology, QuantiFERON‑TB Gold or T‑Spot, HIV if indicated. |
| Screening | Chest X‑ray for TB. Vaccination status (influenza, pneumococcal) updated before infusion. |
| Concomitant medications | Can be combined with immunomodulators (azathioprine, 6‑mercaptopurine). Avoid use with live vaccines during therapy; hold live vaccines 4 weeks before and 2 weeks after infusion. |
| Special populations | • Elderly – no dosage adjustment, but monitor for infections.
• Renal/hepatic impairment – no dose adjustment needed, but monitor liver function.
• Pediatrics – dosing per weight: 4 mg/kg IV (max 300 mg) at Weeks 0, 2, 6, then every 8 weeks. |
---
Common side‑effects (reported in clinical trials)
| Symptom | Incidence |
|---------|-----------|
| Infusion reaction (grade 1–2) | ~10 % |
| Headache | ~6 % |
| Nausea/vomiting | ~5 % |
| Diarrhea | ~4 % |
| Upper respiratory infections | ~9 % |
| Back pain | ~3 % |
Severe infections (e.g., opportunistic fungal infections) are < 0.5 %.
---
Monitoring during therapy
| What to monitor | Frequency |
|-----------------|-----------|
| Clinical response (symptom scores) | At each infusion and follow‑up visit |
| Lab values (CBC, CMP) | Every 3–6 months |
| Infection signs | As clinically indicated; prompt evaluation if fever/respiratory symptoms |
| Drug trough levels / antibodies (if available) | Optional, mainly in research settings |
---
Drug–drug interactions
| Interaction | Impact |
|-------------|--------|
| Other biologics (e.g., anti‑TNF) | Use cautiously; overlapping immunosuppression increases infection risk. |
| Azathioprine/6‑MP | Combination therapy can be beneficial for inducing remission but may increase infection risk. |
| Vaccines | Live vaccines (e.g., varicella, MMR, yellow fever) contraindicated. Inactivated vaccines safe. |
| Other immunosuppressants | Additive immunosuppressive effect – monitor closely. |
| NSAIDs | No known interaction but can increase GI risk; monitor for ulcers. |
---
Cost & Access
* Manufacturer: Takeda Pharmaceutical Co., Ltd.
* Insurance: Most U.S. insurers cover Entyvio once other conventional therapies have failed; prior authorization typically required.
* Patient assistance: Takeda offers the “Entyvio Patient Assistance Program” for eligible patients.
* Formulary: Frequently listed as a second‑line agent after TNF inhibitors for moderate‑to‑severe UC/CD.
---
Practical Tips for Clinicians
1. Patient selection – Ideal for patients with proven mucosal inflammation who have not responded to mesalamine or corticosteroids, and who prefer a gut‑selective mechanism.
2. Infusion precautions – Check for anaphylaxis history; have epinephrine ready. Consider pre‑medication in high‑risk patients.
3. Monitoring adherence – Since infusion is every 8 weeks, schedule appointments early to avoid missed doses.
4. Safety counseling – Educate patients on symptoms of infection, importance of reporting fevers, and to keep up with vaccinations before therapy.
5. Pregnancy planning – Discuss contraceptive use and potential risks; discontinue if pregnancy is confirmed unless benefits outweigh risks.
---
Frequently Asked Questions (FAQ)
| Q | A |
|---|---|
| Is Entyvio safer than anti‑TNF drugs? | It has a lower risk of systemic infections because it spares most immune cells, but opportunistic infections still occur, especially in patients on concurrent immunosuppressants. |
| **Can I stop Entyvio if I’m in remission?